Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADMS

Adamas Pharmaceuticals (ADMS) Stock Price, News & Analysis

Adamas Pharmaceuticals logo

About Adamas Pharmaceuticals Stock (NASDAQ:ADMS)

Advanced Chart

Key Stats

Today's Range
$8.22
$8.22
50-Day Range
$7.97
$8.23
52-Week Range
$4.02
$9.15
Volume
N/A
Average Volume
692,487 shs
Market Capitalization
$376.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Receive ADMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMS Stock News Headlines

Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
Adamas One Corp (JEWL)
See More Headlines

ADMS Stock Analysis - Frequently Asked Questions

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its quarterly earnings results on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.21. The specialty pharmaceutical company had revenue of $25.90 million for the quarter, compared to analysts' expectations of $25.07 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adamas Pharmaceuticals investors own include Rite Aid (RAD), VBI Vaccines (VBIV), Amarin (AMRN), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Exelixis (EXEL).

Company Calendar

Last Earnings
11/11/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMS
Employees
138
Year Founded
2002

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.40 million
Pretax Margin
-71.11%

Debt

Sales & Book Value

Annual Sales
$74.46 million
Price / Cash Flow
N/A
Book Value
($0.47) per share
Price / Book
-17.49

Miscellaneous

Free Float
37,133,000
Market Cap
$376.37 million
Optionable
Optionable
Beta
2.82

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:ADMS) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners